LncRNA colon cancer-associated transcript 1 (CCAT1) in ovarian cancer

P. Coni

First

Writing - Original Draft Preparation

;A. Mateddu

Second

Methodology

;L. Kuqi;G. Pichiri

Methodology

;A. Occhinegro;D. Ratto;G. Orrù

Last

Writing - Review & Editing

2018-01-01

---

Abstract

We read the study published by Lai et al1 with great interest. The complex nature of neoplastic transformation has an enormous impact at various moments of the cancer diagnostics and therapy protocols. Sophisticated individualized therapeutic approaches, supported by an increasing use of tumorspecific molecular tests, are now available2,3. In particular, more details are necessary among molecular differences of primary lesion and its metastases, because these are frequently responsible for the failure of systemic therapy4-6. In this contest, the study published by Lai and Cheng represent an interesting approach in order to study the molecular mechanism of metastasis and proliferation in ovarian cancer (OC). In OC, more than in other types of tumors, morphologic diagnosis is no more sufficient to obtain a qualified therapeutic decision; therefore, the use of new molecular markers is mandatory to improve the clinical management of this type of cancer7. The authors of this study, for the first time, observed that the LncRNA colon cancer-associated transcript 1 (CCAT1) promotes OC proliferation and metastasis.